APA (7th ed.) Citation

P, S., M, O., J, O., M, C., SL, G., SA, I., . . . G, C. (2025). TROPION-Breast05: A randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer. Therapeutic advances in medical oncology, 17, 17588359251327992. https://doi.org/10.1177/17588359251327992

Chicago Style (17th ed.) Citation

P, Schmid, et al. "TROPION-Breast05: A Randomized Phase III Study of Dato-DXd with or Without Durvalumab Versus Chemotherapy Plus Pembrolizumab in Patients with PD-L1-high Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer." Therapeutic Advances in Medical Oncology 17 (2025): 17588359251327992. https://doi.org/10.1177/17588359251327992.

MLA (9th ed.) Citation

P, Schmid, et al. "TROPION-Breast05: A Randomized Phase III Study of Dato-DXd with or Without Durvalumab Versus Chemotherapy Plus Pembrolizumab in Patients with PD-L1-high Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer." Therapeutic Advances in Medical Oncology, vol. 17, 2025, p. 17588359251327992, https://doi.org/10.1177/17588359251327992.